Literature DB >> 16690440

A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT.

Valeria Landoni1, Bianca Saracino, Simona Marzi, Michaele Gallucci, Maria G Petrongari, Enrico Chianese, Michaela Benassi, Giuseppe Iaccarino, Antonella Soriani, Giorgio Arcangeli.   

Abstract

PURPOSE: To assess the influence of setup errors and organ motion in terms of the probability of tumor control and normal-tissue complications by tumor control probability and normal-tissue complication probability. METHODS AND MATERIALS: Twelve patients were treated for prostate cancer with intensity-modulated radiation therapy. Two orthogonal portal images were taken daily. All patients underwent three computed tomography scans during the 8-week treatment time (i.e., baseline, intermediate, and final). The original treatment plans were re-evaluated, taking into account setup errors and organ motion.
RESULTS: The mean shifts +/- standard deviation of the whole patient population in the lateral, anterior-posterior, and craniocaudal direction were 1.0 +/- 1.5 mm, 0.9 +/- 2.1 mm, and 1.9 +/- 2.1 mm, respectively. In most of the recalculated dose-volume histograms, the coverage of clinical target volume was granted despite organ motion, whereas the rectal wall histograms were often very different from the planned ones.
CONCLUSION: We have studied the impact of prostate and rectum motion, as well as setup errors, on dose-volume histograms. The estimate of these effects may have implications for predictive indications when planning intensity-modulated radiation therapy treatments on prostate.

Entities:  

Mesh:

Year:  2006        PMID: 16690440     DOI: 10.1016/j.ijrobp.2006.01.021

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?

Authors:  G Eminowicz; C Dean; O Shoffren; N Macdougall; P Wells; R Muirhead
Journal:  Br J Radiol       Date:  2014-03-20       Impact factor: 3.039

2.  Verification of the dose attenuation of a newly developed vacuum cushion for intensity-modulated radiation therapy of prostate cancer.

Authors:  Toru Takakura; Yoshiyuki Ito; Akinori Higashikawa; Tomohiro Nishiyama; Takashi Sakamoto
Journal:  Radiol Phys Technol       Date:  2016-06-03

3.  Reducing ExacTrac intrafraction imaging uncertainty for prostate stereotactic body radiotherapy using a pre-treatment CBCT.

Authors:  Barry Jordan; Luis Muñoz; Christopher Colyer
Journal:  Phys Eng Sci Med       Date:  2022-04-19

4.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

5.  In-phantom dose verification of prostate IMRT and VMAT deliveries using plastic scintillation detectors.

Authors:  David Klein; Tina Marie Briere; Rajat Kudchadker; Louis Archambault; Luc Beaulieu; Andrew Lee; Sam Beddar
Journal:  Radiat Meas       Date:  2012-08-24       Impact factor: 1.898

6.  Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.

Authors:  Maria Grazia Petrongari; Valeria Landoni; Biancamaria Saracino; Sara Gomellini; Stefano Arcangeli; Giuseppe Iaccarino; Paola Pinnarò; Giorgio Arcangeli; Lidia Strigari
Journal:  J Exp Clin Cancer Res       Date:  2013-12-13

7.  Significance of image guidance to clinical outcomes for localized prostate cancer.

Authors:  Qiuzi Zhong; Hong Gao; Gaofeng Li; Xia Xiu; Qinhong Wu; Ming Li; Yonggang Xu
Journal:  Biomed Res Int       Date:  2014-07-13       Impact factor: 3.411

8.  Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer.

Authors:  Simona Marzi; Biancamaria Saracino; Maria G Petrongari; Stefano Arcangeli; Sara Gomellini; Giorgio Arcangeli; Marcello Benassi; Valeria Landoni
Journal:  J Exp Clin Cancer Res       Date:  2009-08-19

9.  Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity.

Authors:  Gamze Ugurluer; Banu Atalar; Teuta Zoto Mustafayev; Gorkem Gungor; Gokhan Aydin; Meric Sengoz; Ufuk Abacioglu; Mustafa Bilal Tuna; Ali Riza Kural; Enis Ozyar
Journal:  Br J Radiol       Date:  2020-10-29       Impact factor: 3.039

10.  Investigation into the use of a MOSFET dosimeter as an implantable fiducial marker.

Authors:  Stephen F Kry; Michael Price; Zhonglu Wang; Firas Mourtada; Mohammad Salehpour
Journal:  J Appl Clin Med Phys       Date:  2009-01-27       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.